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Radix Pseudostellariaeis used as a tonic drug in traditionalChinesemedicine with immunomodulatingand anti-fatigue activities,
and the polysaccharide is considered as the main active component. The purpose of this study is to examine the eﬀect of the
polysaccharide isolated from Radix Pseudostellariae (PRP) on mouse chronic fatigue syndrome (CFS) induced by intraperitoneal
injection of polyriboinosinic:polyribocytidylic acid (poly I:C), a double-stranded synthetic RNA. It has shown that the fatigue
symptom of mice lasted at least 1 week as evaluated by forced swimming time. PRP (100, 200, 400mgkg−1), orally administered
3 days before poly I:C injection, showed dose-dependent anti-fatigue eﬀects. In addition, poly I:C led to evident alternations in
neuroendocrine and immune systems of mice, such as reduced spontaneous activity and learning ability, declined serum level of
corticosterone, increased weight indexes and T lymphocyte numbers in thymuses and spleens, and increased CD4+/CD8+ ratio
but decreased proliferation ability of T lymphocytes in spleens. PRP alleviated the abnormalities caused by poly I:C, and restored
the function of hosts to normal conditions. The ﬁndings suggest that PRP is beneﬁcial to CFS, and the underlying mechanisms of
action involve neuroendocrine and immune systems.
1.Introduction
Chronic fatigue syndrome (CFS) was ﬁrst deﬁned in 1988
by the US Centers for Disease Control and Prevention as
unexplained disabling fatigue lasting more than 6 months,
together with a combination of non-speciﬁc accompanying
symptoms [1]. CFS patients usually experience substantial
reductions in occupational, educational and social func-
tions, which collectively hamper the quality of life [2]. In
addition, CFS is a debilitating syndrome with a cluster of
multi-system dysfunctions [3], mainly involving the neu-
roendocrine and immune systems, and usually inﬂuencing
other systems as well [4–7]. The pathogenesis of CFS
probably includes immune system abnormalities, chronic
immune activation, hypothalamic-pituitary-adrenal (HPA)
axis dysfunction, brain anomalies, emotional stress and
exogenous insults [8]. However, little is known about the
underlying mechanisms of the fatigue symptoms in any
clinical condition. Viral infection is of vital importance
to CFS as considered from an etiologic aspect. Emotional
stress appears to be important as well, as it impairs the
normal function of the immune system against infections.
Furthermore, emotional stress has beenshown to determine,
whether or not, an individual develops fatigue symptom
upon virus infection, and can lead to the activation of the
HPA axis. Likewise, a number of studies have focused on
altered immune function in CFS, and immune function
anomalies havebeen consideredaspotential explanationsfor
the symptom complex or as possible predisposing factors for
altered responses to infections.
Polyriboinosinic:polyribocytidylic acid (poly I:C), a
double-stranded synthetic RNA, is frequently applied in
animal experiments to mimic a condition of viral infection.
Recently, Katafuchi et al. [9] reported that intraperitoneal
i n j e c t i o no fp o l yI : Ci nr a t sr e s u l t e di nas i g n i ﬁ c a n ta n d
persistent reduction of spontaneous running wheel activity,
which could be considered as an animal model of immuno-
logically chronic fatigue with mechanisms closely related to
the neuronal-endocrine-immune interactions.
Alternative medicines including Traditional Chinese
Medicine have advantages of being eﬀective to alleviate
symptoms of CFS such as fatigue, disordered sleep, cognitive2 Evidence-Based Complementary and Alternative Medicine
handicap and other complex complaints with minor side
eﬀects. The underlying mechanisms mainly include regulat-
ing immune function, adjusting abnormalities in the HPA
axisandantioxidation[10].Pinuspinaste barkcouldalleviate
fatigue and activate the endogenous antioxidant enzyme
system [11]. Angelica sinensis and Matricaria chamomilla
extracts could ameliorate fatigue and sleep disturbances
[12]. Panax ginseng has been used for centuries in Oriental
folk medicine against fatigue. It could elevate movement
ability and resist against CNS fatigue in mice [13]. Clinically,
Ginseng could alleviate chronic fatigue, reducing fatigue
severity and curtailing fatigue duration [14]. Acanthopanacis
senticosus or Siberian ginseng showed ameliorating eﬀects on
CFS in a placebo-controlled clinical study [15]. Crataegus
oxyacantha showed a signiﬁcant increase in exercise time and
an improvement in life quality in a three month placebo-
controlled, randomized, double-blind trial [16]. Eucommia
ulmoides leaves enhanced the 3-hydroxy-acyl-CoA dehydro-
genase speciﬁc activity and lactate dehydrogenase speciﬁc
activity in the skeletal muscle, suggesting that exercising
and intaking of the leaf cooperatively could decrease the
possibility of lactate accumulation in skeletal muscle and
that the administration of E. ulmoides leaves along with
low intensity training can enhance the ability of a muscle
to resist fatigue [17] Rhodiola rosea is used as a central
stimulant, antidepressant and antifatigue drug. Rhodiola
rosea extract showed a signiﬁcant improvement in the total
mental performance [18] Oryza sativa, Gentiana lutea sym-
phyandra and Trichopus zeylanicus-treated mice performed a
better physical endurance in forced swimming tests [19–21].
Withania somnifera,Q u e r c e t i na n dHypericum perforatum L.
have been used for the treatment of CFS with the purpose of
reducing lipid peroxidation, restoring the glutathione levels
and increasing the superoxide dismutase levels in the brains
of CFS mice [22]. Ginkgo biloba and Vaccinium myrtillus
(bilberry) have also been reported containing beneﬁcial
antioxidants for CFS [23].
Radix Pseudostellariae, the roots of Pseudostellaria het-
erophylla, is widely used as a tonic drug in China for the
treatment of splenic asthenia syndrome, which partially
manifests features of CFS. Macromolecule polysaccharides
have long been recognized as the main active component
of Radix Pseudostellariae [24]. They possess antiinfectious,
antioxidative and immunomodulating activities [25–27],
suggesting that they might be beneﬁcial to CFS. In the
present study, the antifatigue eﬀects of the polysaccharides
were evaluated in poly I:C-induced mouse model of CFS.
The mechanisms of action were addressed in terms of
neurological, endocrine and immune regulations.
2.Materialsand Methods
2.1. Chemicals and Reagents. Poly I:C was purchased from
Guangdong BangMin Pharmaceutical Co., Ltd., Guangdong,
China. Corticosterone radioimmunity kit was purchased
from Beijing PuerWeiye Biotechnology, Ltd., Beijing, China.
Concanavalin A (Con A) was purchased from Sigma, USA.
Phycoerythrin (PE) antimouse CD4 (L3T4, Cat#: BM0404),
PE antimouse CD8 (Lyt-2, Cat#: EM0804), ﬂuorescein
isothiocyanate (FITC) antimouse CD3 (Cat#: EM0301) and
lysing solution were purchased from MultiSciences Biotech
Co., Ltd., Shanghai, China.
2.2. Animals. Male ICR mice (18–22g) were purchased from
the experimental animal centre of China Pharmaceutical
University. The animals were housed with free access to
standard laboratory chow and water at 23 ± 2◦Cw i t ha
dark and light cycle of 12h each. Animal experiments were
conducted in accordance with current ethical regulations for
institutional animal care and use of China Pharmaceutical
University. The study was approved by the Institutional
Ethical Committee of China Pharmaceutical University.
2.3. Preparation of PRP. Radix Pseudostellariae was pur-
chased from Anhui Province, China, and was authenticated
by Professor Mian Zhang, China Pharmaceutical University.
Powdered crude drugs (400g) were extracted three times
by reﬂuxing with 80% ethanol (1L) at 90◦Cf o r2 ∼3h
each time. After ﬁltration, the gruﬀs were extracted again
for three times with water (1.5L) at 90◦Cf o r2 - 3 he a c h
time. The extracted solution was condensed to 400mL and
deproteinated by applying the Sevag method. The solution
was then added to absolute ethyl alcohol until the ethanol
concentration was 80% and kept overnight, followed by
ﬁltration. The precipitate was dissolved with water (100mL)
and then added absolute ethyl alcohol until the ethanol
concentration was 80%, ﬁltrated and repeated once again.
The precipitate was washed with 95% ethanol, absolute ethyl
alcohol and acetone by turns, and then dried at 50◦C, leaving
an ivory white powder. The yield ratio of the polysaccharides
in the dried roots was 2.13%, and the purity was 72.65%
as measured by a phenol-sulfuric acid colorimetric method
with glucose as a reference. The crude dried PRP was
dissolved in distilled water just before use.
2.4. Therapy Regimen. F i f t ym i c ew e r er a n d o m l yd i v i d e d
into ﬁve groups: 1: normal; 2: control; 3: PRP (100mgkg−1);
4: PRP (200mgkg−1); 5: PRP (400mgkg−1). PRP was orally
administered with a volume of 0.2mL/10g body weight at
8:00 am for consecutive 17 days. Normal and control mice
weregivenorallyanequalvolumeofvehicle.Onday4,except
the mice in normal group, all mice were intraperitoneally
injected poly I:C (5mgkg−1) to induce CFS.
2.5. Forced Swimming Test. O nd a y1 ,4 ,7 ,1 0a n d1 3a f t e r
injection of poly I:C, forced swimming test was carried out
in a plastic pool (48 × 36 × 29cm). The water depth and
temperature were 20cm and 22 ± 1◦C, respectively. Mice
were loaded 5% of the body weight of lead threads at the
bases ofthetails.Theywere thenforcedtoswim untilfatigue,
d e ﬁ n e da sf a i l u r et or i s et ot h es u r f a c eo ft h ew a t e rt ob r e a t h e
within an 8-s period. The time until fatigue was recorded.
2.6. Spontaneous Activity. On day 3 before injection, day
1 and 7 after injection of poly I:C, open ﬁeld test was
performed toevaluatethelocomotiveand explorativebehav-
ior in a novel circumstance. The open ﬁeld apparatus wasEvidence-Based Complementary and Alternative Medicine 3
acylindrical box(diameter: 30cm,height:20cm),which was
divided into 19 equal grids on the ﬂoor. Mice were placed
individually on the centre of the apparatus, and were allowed
to move freely for 5min. During the test, the total number of
cross points was manually recorded.
2.7. Learning Ability. On day 14 after injection of poly I:C,
step-downtestwasperformedtoexaminethelearningability
of mice. The apparatus consisted of a transparent acrylic
chamber with an electriﬁable grid ﬂoor. A rubber platform
(diameter: 4.5cm, height: 4.5cm) was placed on the grid
ﬂoor. Mice were allowed to move freely in the chamber for
3min without current in the electriﬁable grid ﬂoor. In the
following 5min, mice were put on the platform with current
in the electriﬁable grid ﬂoor. If they stepped down from the
platform (“error trial”), they were punished by an electric
foot shock (36V, AC). The error number was recorded as the
ﬁnal grade for the learning ability test.
2.8. Assay of Serum Corticosterone Level. On day 14 after
poly I:C injection, mice of all groups were sacriﬁced, and
the peripheral blood samples (0.2mL per mouse) were
collected. The blood samples were centrifuged for 10min at
4◦C, 3000rmin−1. Sera were stored at −70◦C until assay.
Corticosterone level was measured by radioimmunoassay
according to the manufacturer’s instructions.
2.9.CD4+ TandCD8 + TlymphocytesinPeripheral Blood. On
day 14 after poly I:C injection, anticoagulated blood (0.2mL
per mouse) was collected, and stained with 5μLo fP Ea n t i -
mouse CD4, PE antimouse CD8 and FITC antimouse CD3,
respectively. The blood was incubated in the dark at 4◦C
for 1h. Then, the lysing solution (2mL) was added to lyse
erythrocytes. The mixtures were incubated in the dark at
room temperature for 30min, and centrifuged at 4◦Cf o r
1500rmin−1. Then, they were washed with 2mL PBS, and
dissolved with PBS (500μL). The cells were analyzed on a
ﬂow cytometer, using cell quest software.
2.10. Weighing and Histological Analysis of Immune Organs.
On day 14 after poly I:C injection, spleens and thymuses
of mice in each group were removed and weighed, and
the weight indexes (mgg−1 b.w.) were calculated. Then
they were ﬁxed in formaldehyde, sectioned and embedded
in paraﬃn, and sliced for hematoxylin and eosin staining.
Several parameters, including peripheral cortex thickness
of thymus, numbers of splenic corpuscles and periarterial
lymphatic sheaths, splenic sinusoid and splenic cord size,
were evaluated in the histological analysis.
2.11. Spleen Cell Proliferation Assay. On day 14 after poly
I:C injection, spleens of six mice in each group were gently
homogenized and repeatedly pipetted to attain a single
splenocyte suspension. The cells were washed twice with
ice-cold PBS and separated by nylon mesh (cell viability >
95%), and then seeded in 96-well culture plates at a ﬁnal
concentration of 5 × 106 cells/well in a RPMI-1640 medium
supplemented with 10% FBS. Splenocytes, treated with or
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Figure 1: Eﬀect of PRP on the body weights of mice treated with
poly I:C. PRP was administered orally from 3 days before poly I:C
injection for 17 days. Data are expressed as means ± SEM (n = 10).
∗P<. 05; ∗∗P<. 01 versus control.
without mitogen Con A (5μgmL −1), were incubated for
68h at 37◦Ci na5 %C O 2 incubator. Subsequently, 20μLo f
MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide) (0.5mgmL−1) was added into each well, and
the cells were incubated for another 4h. After that, the
supernatant was removed and the formazan crystals were
dissolved using DMSO (dimethyl sulphoxide) (150μL). The
absorbance at 570 nmwas read with a Model1500 Multiskan
spectrum microplate Reader(Thermo, Waltham, MA, USA).
2.12. Statistics. All values were expressed as mean ± SEM.
Data were statistically analyzed by ANOVA followed by post
hoc Tukey test. Diﬀerences were considered signiﬁcant at
P<. 05.
3.Results
3.1. PRP Increased the Body Weights of Mice. Body weight,
an indicator of health status, was measured every other day.
Poly I:C injection resulted in a rapid and persistent decrease
in the body weights of mice (Figure 1). PRP (100, 200,
400mgkg−1) dose-dependently increased the body weights
of mice during the 2 weeks after the injection of poly
I:C. Statistically signiﬁcant increase was observed in PRP
(400mgkg−1)-treated group from day 8 to 14.
3.2. Anti-Fatigue Activity of PRP. The forced swimming
time of mice was considered as an indicator of fatigue.
During 13 days of trial period, the forced swimming time
of normal mice was within 80 to 90 min. At 6h after poly
I:C injection, the average forced swimming time of control
group decreased sharply, and lasted at least for 1 week. From
the second week, it gradually recovered, and yet, not reached
the baseline level until day 13. PRP (100, 200, 400mgkg−1)4 Evidence-Based Complementary and Alternative Medicine
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Figure 2: Eﬀect of PRP on chronic fatigue induced by poly I:C
in mice. PRP was administered orally from 3 days before poly
I:C injection for 17 days. Forced swimming test was performed at
indicated days. Data are expressed as means ± SEM (n = 10).
∗P<. 05 versus control.
dose-dependentlyprolonged the forced swimming time dur-
ingthefullexperimentperiod.Especially,PRP(400mgkg−1)
showed a statistically signiﬁcant eﬀect in the ﬁrst week
(Figure 2).
3.3. PRP Increased Spontaneous Activity. Before and after
poly I:C injection, the spontaneous activity of ﬁve groups
of mice was examined by open ﬁeld test. The results
were presented in Figure 3. Baseline levels of spontaneous
activities were of the similar level among all groups with-
out signiﬁcant diﬀerences. At 4h after poly I:C injection,
spontaneous activity of mice in control group decreased
signiﬁcantly compared with that of the normal group. PRP
(100,200,400mgkg−1)showedadose-dependentincreasein
spontaneous activity. On day 7, the spontaneous activities of
mice in both control and PRP-treated groups restored almost
to the baseline level.
3.4. PRP Improved the Learning Ability. On day 14 after poly
I:C injection, the step-down latency of passive avoidance
response (number of errors) of mice in control group was
apparently longer than that of normal group, suggesting that
poly I:C resulted in decline of learning ability. PRP (100,
200, 400mgkg−1) treatment decreased the number of errors
of mice in a dose-dependent manner. Statistically signiﬁcant
improvementsoflearningabilityweredisplayedinPRP(200,
400mgkg−1)-treated groups (Figure 4).
3.5. PRP Increased the Serum Corticosterone Level. As shown
in Figure 5, the average serum corticosterone level of mice
in control group was signiﬁcantly decreased in comparison
with normal group on day 14 after poly I:C treatment.
PRP (100, 200, 400mgkg−1) dose-dependently elevated the
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Figure 3: Eﬀect of PRP on spontaneous activity in mice treated
with poly I:C. Mice were placed individually on the center of the
apparatus, and were allowed to move freely for 5min. The total
number of cross points was manually recorded at indicated days
after injection of poly I:C. PRP was administered orally from 3 days
before poly I:C injection for 17 days. Data are expressed as means ±
SEM (n = 10). ∗P<. 05, ∗∗P<. 01 versus control.
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Figure 4: Eﬀect of PRP on learning ability in mice treated with
poly I:C. The error number of the learning training was recorded
as the learning grade on Day 14 after injection of poly I:C. PRP
was administered orally from 3 days before poly I:C injection for
17 days. Data are expressed as means ± SEM (n = 10). ∗P<. 05
versus control.
corticosterone level, and completely reversed the decrease of
serum corticosterone at the dose of 400mgkg−1.
3.6. Impacts of PRP on Immune Organ Index. Poly I:C
treatmentresultedintheincreasesofboththymusandspleen
indexes of mice. PRP (100, 200, 400mgkg−1)d i dn o ta ﬀect
thethymusindex,butdose-dependentlydecreasedthespleen
index. The spleen index of mice in PRP (400mgkg−1)-
treated group was close to the normal value on day 14 after
poly I:C injection (Figure 6).
3.7. Histological Findings of Immune Organs. Each thy-
mus lobule has a peripheral cortex consisting of a dense
populationofthymocytes which surround the lightly stainedEvidence-Based Complementary and Alternative Medicine 5
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Figure 5: Eﬀect of PRP on serum corticosterone level in mice
treated with poly I:C. Peripheral blood samples were collected with
0.2mL per mouse on Day 14 after injection of poly I:C. Serum
corticosteronelevelwasmeasured by radioimmunoassayassay.PRP
was administered orally from 3 days before poly I:C injection for
17 days. Data are expressed as means ± SEM (n = 10). ∗P<. 05,
∗∗P<. 01 versus control.
central medulla. After treated with poly I:C, the thickness
and the thymocyte numbers in the peripheral cortex of
mouse thymus were obviously increased together with a
compacted arrangement of thymocytes. PRP (100, 200,
400mgkg−1) reduced the thymocyte population to normal
level (Figure 7).
There are white pulp, red pulp and marginal zone in
spleenparenchyma. Whitepulpconsistsofspleniccorpuscles
and periarterial lymphatic sheaths. Red pulp consists of
splenic sinusoid and splenic cord. Compared with normal
group, size of both splenic corpuscles in white pulp and
periarterial lymphatic sheaths in red pulp were obviously
increased in control group, suggesting that poly I:C led to
increasetheTlymphocytepopulationinspleens.Inaddition,
splenic sinusoid in red pulp distended and engorged slightly
in control group. PRP (100, 200, 400mgkg−1) ameliorated
the histological changes in spleens to diﬀerent degrees
(Figure 8).
3.8. PRP Regulated the Ratio of CD4+ and CD8+ TL y m -
phocytes in Peripheral Blood. Peripheral blood of mice was
collected on day 14 after poly I:C treatment for the detection
of T lymphocyte population using ﬂow cytometry analysis.
It was shown that poly I:C resulted in a remarkable increase
of CD4+/CD8+ ratio by increasing CD4+ Tl y m p h o c y t e
percentage and decreasing CD8+ T lymphocyte percentage.
PRP (100, 200, 400mgkg−1) modulated the percentages of
the two types of lymphocytes and restored the CD4+/CD8+
r a t i ot on o r m a l( Table 1).
3.9. PRP Increased the Proliferation Ability of Spleen T Lym-
phocytes. The proliferation of mouse spleen T lymphocytes
was induced by Con A in vitro.A ss h o w ni nFigure 9,t h e
proliferation ability of T lymphocytes in poly I:C-treated
group was signiﬁcantly reduced. PRP at doses of 100, 200
and 400mg kg−1 promoted the proliferation ability, and the
Table 1: Eﬀect of PRP on CD4+ and CD8+ T lymphocyte
populations in peripheral blood of mice treated with poly I:C.
Groups Dose
(mgkg−1)
CD4+/CD3+
(%)
CD8+/CD3+
(%)
CD4+/CD8+
Normal — 66.8 ± 1.1∗ 29.8 ± 4.0 2.4 ± 0.3∗
Control — 74.2 ± 2.2 24.1 ± 1.6 3.5 ± 0.2
PRP
100 72.3 ± 0.7 24.7 ± 1.2 2.9 ±0.1
200 71.3 ± 3.0 25.4 ± 2.0 2.9 ± 0.3
400 71.5 ± 1.1 26.1 ± 0.7 2.7 ± 0.1∗
Anticoagulated blood 0.2mL of each mouse was collected on day 14 after
injection of poly I:C. The cell populations were analyzed by ﬂow cytometry.
Data are expressed as means ± SEM (n = 5). ∗P<. 05 versus control.
proliferation index in PRP (400mgkg−1)-treated group was
close to that of normal group.
4.Discussion
CFS is characterized by clinically unexplained fatigue, lasted
at least for six months, which is not the outcome of
ongoing exertion and is not substantially alleviated by rest.
Although the exact pathogenesis of CFS remains unclear,
current hypotheses postulate that special virus infection and
immune dysfunction relevant to infection are contributed
to the occurrence of CFS. For experimental purpose, several
animal models of CFS have been established by injecting the
bacterial antigen from Corynebacterium parvum and Brucella
abortus [28–30], injection of poly I:C, and 15-day exposure
to forced swimming [31]. Among these models mentioned
above, poly I:C- or B. abortus antigen-induced fatigue is able
to persist for more than 1 week in contrast to the short
duration induced by C. parvum antigen. In addition, as CFS
is not the result of ongoing exertion, fatigue due to forced
swimming for 15 days seems to be an improper model of
CFS. Therefore, in the present study, we evaluated the anti-
CFS eﬀect of PRP using poly I:C model, and explored the
underlying mechanisms of PRP in terms of neuroendocrine
and immune modulation.
Forced swimming time and spontaneous running wheel
activity are usually adopted to represent the physical work
capacity and fatigue condition of animals. In the current
study, the forced swimming time of normal mice was nearly
stable during the 2 weeks. Intraperitoneal injection of poly
I:C resulted in a persistent decline of mouse swimming
time, indicating that it can induce chronic fatigue condition
in mice as in rats [9]. PRP, orally administered prior to
poly I:C injection, prolonged mouse swimming time in a
dose-dependent manner. Further, we found that poly I:C
treatment led to a marked reduction of spontaneous activity
of mice in the open ﬁeld test by near 50% as compared with
the normal group, and PRP exhibited ameliorating eﬀect
on the spontaneous activity in poly I:C-treated mice. The
ﬁndings demonstrated that PRP had beneﬁcial eﬀects on
chronic fatigue.
It is generally accepted that the persistent fatigue is
not due to peripheral problems such as muscular weakness
and muscle or joint pain, but involves complex central6 Evidence-Based Complementary and Alternative Medicine
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Figure 6: Eﬀect of PRP on immune organ weight of mice treated with poly I:C. Mouse thymuses and spleens were removed and weighed
on Day 14 after injection of poly I:C. Thymus and spleen indexes were calculated. PRP was administered orally from 3 days before poly I:C
injection for 17 days. Data are expressed as means ± SEM (n = 10). ∗P<. 05 versus control.
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Figure 7: Representative histological changes in thymuses (hematoxylin and eosin, H&E, ×100). Thymuses were removed on Day 14 after
poly I:C injection. Peripheral cortex thickness of thymus was evaluated.
mechanisms [32]. Under the condition of chronic fatigue,
cytokines produced in the brain exert various central
actions, including activation of sympathetic nervous system
and hypothalamic-pituitary axis, impairment of learning
memory and inﬂuence of peripheral cellular immunity [33].
Ithasbeenreportedthatnotonlypersonalactivityreduction,
but cognitive disturbances are also exhibited in CFS patients
[2]. Poly I:C is thought to induce central fatigue through
modulating IFN-α and 5-HT expressions in the brain [34].
In the current study, it remarkably impaired the cognitive
and learning ability of mice in the step down test. PRP could
dose-dependently reverse the learning ability decline caused
by poly I:C. Since PRP is a soluble micromolecule, it is
probably diﬃcult to cross the blood-brain barrier (BBB)and
activate gliacytesdirectly. PRPmay passively cross the BBBat
“leaky” regions where the BBB is not intact, such as the cir-
cumventricularorgans (CVO’s),and directly act onendothe-
lial cells of brain vasculature or glial cells in the CVO’s,
inducing the synthesis/release of central cytokines. On the
other hand, PRP may activate immune system to release a lot
of cytokines, which aﬀect central nervous system indirectly.
The HPA axis carries out the functions to maintain
homeostasisbetweenphysicalandpsychologicalstress. There
are a few reports demonstrating that the basal serum cortisol
level was below average in CFS patients [35]. In the present
study, poly I:C treatment led to a remarkable decline of
mouse serum corticosterone level. PRP elevated the serum
corticosterone level in a dose-dependent manner, suggesting
that it can modulate the function of HPA axis under the
condition of chronic fatigue.Evidence-Based Complementary and Alternative Medicine 7
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Figure 8: Representative histological changes in spleens (hematoxylin and eosin, H&E, ×100). Spleens were removed on Day 14 after poly
I:C injection. Numbers of splenic corpuscles and periarterial lymphatic sheaths, splenic sinusoid and splenic cord size were evaluated.
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Figure 9: Eﬀect of PRP on T lymphocyte proliferation of mice induced by Con A. PRP was administered orally from 3 days before poly I:C
injectionfor17days.Splenocytes ofmicewere treated withorwithoutmitogenConAonDay14afterinjectionofpolyI:C.Theproliferation
ability was evaluated by MTT assay. Data are expressed as means ± SEM (n = 6). ∗P<. 05 versus control.
CFS patients have speciﬁc immune dysfunction proﬁles
characterizedbyactivationoflymphoidpopulationsbutsup-
pression of some immune responses [36, 37]. The immune
system of CFS patients reacts as if it is continuously com-
bating an infection no matter whether an infectious agent is
actually present at the time. But when the patients are chal-
lenged with stressors such as infections, immune responses
may be blunted due to the production of anti-inammatory
cytokines [38]. Mihaylova et al. [39] indicated that this
pattern of dysfunction comprised a hyperinammatory rest-
ing state and targeted immunosuppression of responses.
Substantial evidence has suggested that most of CFS patients
have one or more immunological abnormalities related to
infectious disorders [40]. In the present study, poly I:C led
to a signiﬁcant increase of both weights and lymphocyte
numbers in thymuses and spleens, two important immune
organs, suggesting that it might induce a persistent status
of immune activation in mice. Moreover, T lymphocyte,
an important eﬀector cell in acquired immunity, can be
divided into two subclasses, CD4+ T cells and CD8+ T cells.
Of which, CD4+ T cells assist and induce the activation
of T cells and B cells, while CD8+ T cells impede the
activated B cells producing antibody. The CD4+/CD8+ ratio
is an important indicator for assessing the function of
cell-mediated immunity. Patients with autoimmune diseases
have high CD4+/CD8+ ratio in their blood, indicating that
imbalance between T lymphocyte subclasses could impair
the immune system and result in diseases. Generally, poly
I:C is recognized by toll-like receptor 3 located at the antigen
presenting cells (APC). The ligand-receptor recognition
leads to IFN-α/β production, followed by antigen-speciﬁc
Tc e l la c t i v a t i o na n dd i ﬀerentiation into eﬀector cells. In8 Evidence-Based Complementary and Alternative Medicine
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Figure 10: The hypothetical mechanisms of PRP against CFS in views of neurological, endocrine and immune modulation.
the present study, poly I:C led to a remarkable increase
of CD4+/CD8+ ratio in peripheral blood of mice by up-
regulating CD4+ T cells and down-regulating CD8+ T cells,
which further demonstrates that poly I:C could induce
chronic immune activation, a typical pathological feature
of CFS patients. In addition, T lymphocytes derived from
spleens of poly I:C-treated mice showed hyporesponsiveness
to the stimulation of Con A, indicating that poly I:C actually
induced a suppression of immune responses. PRP signiﬁ-
cantly ameliorate the immunological anomalies caused by
poly I:C through down-regulating spleen index, lymphocyte
numbers and CD4+/CD8+ ratio in the peripheral blood as
well as reversing the hyporesponsiveness of T cells in spleens.
Inconclusion,intraperitoneal injectionofpolyI:Cwould
lead to a chronic fatigue status in mice, as mainly demon-
strated by persistent decrease of forced swimming time and
spontaneous activity, which was accompanied by neuroen-
docrine and immunological abnormalities. PRP eﬀectively
alleviated the chronic fatigue, and showed a potential
preventiveand therapeuticeﬀectforhumanCFS(Figure 10).
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